Similarly, HPGDS was also expressed highly in grades 2, 3, and 4 gliomas lacking the 1p/19q co-deletion, further suggesting that high levels of HPGDS predict poorer patient outcomes (Figure 6C,D). This evidence concerns the gene HPGDS and central nervous system cancer.